Growing adoption of high-content screening techniques in drug discovery and rising incidence of cancer primarily drives the market for live cell imaging. The growth in research funding and rising government funding and investment in regenerative medicine research will also support the market growth in the coming years. However, the high cost of high-content screening systems is limiting the overall adoption of these products.
According to market research report, “Live Cell Imaging Market by Product (Instruments, Consumables, Software, Services) Application (Cell Biology, Drug Discovery) Technology (Time-lapse Microscopy, FRET) End User (Contract Research Organization, Research Institutes) – Global Forecast to 2025″, The global live cell imaging market size is projected to reach USD 2.8 billion by 2025 from USD 1.8 billion in 2020, at a CAGR of 8.8% during the forecast period.
Currently, no effective treatment for COVID-19 is available in the form of vaccines or antiviral drugs, and patients are currently treated symptomatically. According to the WHO, there are 70 vaccine candidates under development, and three candidates are already being tested in human trials.
The traditional method of toxicity and drug safety studies involves the screening of large libraries through high-throughput screening. This method is expensive, has a low success rate, and is resource- and time-consuming.
𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐆𝐫𝐚𝐛 𝐏𝐃𝐅 @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163914483
The high price of these instruments is also a concern for several pharmaceutical companies as they require multiple HCS systems in their R&D activities (thus increasing the total cost spent on these systems). In addition to the high procurement costs, the maintenance costs and several other indirect expenses increase the total cost of ownership of these instruments.
Currently, China accounts for about 20% of the global R&D spending and is the second-largest investor in R&D, globally, after the US. The country is projected to overtake the US in R&D spending by 2023 (Source: Council on Foreign Relations). Cost savings and a lack of regulations are among the most important drivers boosting preclinical activities in China.
The growing funding and investments in life science research, availability of highly skilled personnel, and a favorable regulatory environment are the other major factors supporting this trend. Moreover, currently, China has many CROs that provide preclinical and clinical research services to multinational pharmaceutical companies.
Get Free Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=163914483
Upcoming Trends — Running live cell imaging experiments successfully can be a major challenge. The conditions under which cells are maintained under microscopes decide the success or failure of the experiment. Therefore, maintaining living cells on slides is the most crucial part of the experiment. The cells used in experiments should be in good condition and function normally under a microscope in the presence of synthetic fluorophores or fluorescent proteins.
Growth Opportunities — Emerging markets such as Brazil, Russia, India, and China are expected to offer significant opportunities for the growth of the live cell imaging market. This can primarily be attributed to the growing R&D funding for various research organizations in these countries.
